UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 49

Sortiert nach

Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events

Pharmacology & therapeutics (Oxford), 2023-10, Vol.250, p.108507-108507, Article 108507

2023

Volltextzugriff (PDF)

Marked plaque regression in homozygous familial hypercholesterolemia

Atherosclerosis, 2021-06, Vol.327, p.13-17

2021

Volltextzugriff (PDF)

Real-world experience of long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and not treating with lipoprotein apheresis

Journal of clinical lipidology, 2024-05

2024

Volltextzugriff (PDF)

Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia

Circulation (New York, N.Y.), 2024-01, Vol.149 (5), p.343

2024

Volltextzugriff (PDF)

A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects

Atherosclerosis, 2020-12, Vol.314, p.33-40

2020

Volltextzugriff (PDF)

How can we improve the prognosis of patients with homozygous familial hypercholesterolemia?

Atherosclerosis, 2024-06, Vol.393, p.117551, Article 117551

Harada-Shiba, Mariko

2024

Volltextzugriff (PDF)

Novel emerging therapies in atherosclerosis targeting lipid metabolism

Expert opinion on investigational drugs, 2020-06, Vol.29 (6), p.611-622

2020

Volltextzugriff (PDF)

The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

JACC. Advances (Online), 2023-11, Vol.2 (9), p.100648, Article 100648

2023

Volltextzugriff (PDF)

Evinacumab Reduces Triglyceride-Rich Lipoproteins in Patients with Hyperlipidemia: A Post-Hoc Analysis of Three Randomized Clinical Trials

Cardiovascular drugs and therapy, 2024-03

2024

Volltextzugriff (PDF)

Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia

Pharmacological research, 2020-03, Vol.153, p.104653, Article 104653

2020

Volltextzugriff (PDF)

ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets

Current atherosclerosis reports, 2021-03, Vol.23 (5), p.20-20, Article 20

2021

Volltextzugriff (PDF)

Angiopoietin-like proteins as therapeutic targets for cardiovascular disease: focus on lipid disorders

Expert opinion on therapeutic targets, 2020-01, Vol.24 (1), p.79-88

2020

Volltextzugriff (PDF)

Lipid metabolism and the targeting of angiopoietin-like 3: Experimental drugs under development

Expert opinion on investigational drugs, 2023-03, Vol.32 (3), p.177-180

2023

Volltextzugriff (PDF)

Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia

Expert opinion on biological therapy, 2022-07, Vol.22 (7), p.813-820

2022

Volltextzugriff (PDF)

Review of recent clinical trials and their impact on the treatment of hypercholesterolemia

Progress in cardiovascular diseases, 2022-11, Vol.75, p.90-96

2022

Volltextzugriff (PDF)

Evinacumab for treatment of familial hypercholesterolemia

Expert review of cardiovascular therapy, 2021-08, Vol.19 (8), p.739-751

2021

Volltextzugriff (PDF)

Evinacumab Therapy for Homozygous Familial Hypercholesterolemia: Driving Lipoprotein Clearance Via the Road Less Taken

JACC. Advances (Online), 2023-11, Vol.2 (9), p.100646

Toth, Peter P

2023

Volltextzugriff (PDF)

Efficacy and Safety of Evinacumab for the Treatment of Hypercholesterolemia: A Meta-Analysis

Journal of cardiovascular pharmacology, 2021-09, Vol.78 (3), p.394

2021

Volltextzugriff (PDF)

Individualized dosing of evinacumab is predicted to yield reductions in drug expenses

Journal of clinical lipidology, 2023-05, Vol.17 (3), p.401-405

2023

Volltextzugriff (PDF)

Evinacumab-dgnb (Evkeeza-REGN1500), A Novel Lipid-Lowering Therapy for Homozygous Familial Hypercholesterolemia

Cardiology in review, 2024-03, Vol.32 (2), p.180

2024

Volltextzugriff (PDF)

Emerging lipid lowering agents targeting LDL cholesterol

Postgraduate medicine, 2020-07, Vol.132 (5), p.433-440

Wójcik, Cezary

2020

Volltextzugriff (PDF)

Current Treatment Options in Homozygous Familial Hypercholesterolemia

Pharmaceuticals (Basel, Switzerland), 2022-12, Vol.16 (1), p.64

2022

Volltextzugriff (PDF)

How ANGPTL3 Inhibition Will Help Our Clinical Practice?

Current atherosclerosis reports, 2023, Vol.25 (1), p.19-29

2023

Volltextzugriff (PDF)

Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia

Journal of clinical medicine, 2022-12, Vol.12 (1), p.168

2022

Volltextzugriff (PDF)

New approaches to address dyslipidemia

Current opinion in lipidology, 2017-12, Vol.28 (6), p.452-457

Parhofer, Klaus G

2017

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(45)
Zeitungsartikel
(4)

Sprache

Englisch
(49)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Evinacumab
(49)
Life Sciences & Biomedicine
(42)
Science & Technology
(42)
Cardiovascular System & Cardiology
(21)
Humans
(21)
Cholesterol
(18)
Pharmacology & Pharmacy
(18)
Cardiac & Cardiovascular Systems
(17)
Angiopoietin-Like Protein 3
(13)
Homozygous Familial Hypercholesterolemia
(13)
Cardiovascular Disease
(11)
Hypercholesterolemia
(11)
Triglycerides
(11)
Angptl3
(10)
Monoclonal Antibodies
(9)
Peripheral Vascular Disease
(8)
Statins
(8)
Bempedoic Acid
(7)
Cholesterol, Ldl
(7)
Familial Hypercholesterolemia
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events

Marked plaque regression in homozygous familial hypercholesterolemia

Real-world experience of long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and not treating with lipoprotein apheresis

Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia

A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects

How can we improve the prognosis of patients with homozygous familial hypercholesterolemia?

Novel emerging therapies in atherosclerosis targeting lipid metabolism

The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Evinacumab Reduces Triglyceride-Rich Lipoproteins in Patients with Hyperlipidemia: A Post-Hoc Analysis of Three Randomized Clinical Trials

Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia

ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets

Angiopoietin-like proteins as therapeutic targets for cardiovascular disease: focus on lipid disorders

Lipid metabolism and the targeting of angiopoietin-like 3: Experimental drugs under development

Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia

Review of recent clinical trials and their impact on the treatment of hypercholesterolemia

Evinacumab for treatment of familial hypercholesterolemia

Evinacumab Therapy for Homozygous Familial Hypercholesterolemia: Driving Lipoprotein Clearance Via the Road Less Taken

Efficacy and Safety of Evinacumab for the Treatment of Hypercholesterolemia: A Meta-Analysis

Individualized dosing of evinacumab is predicted to yield reductions in drug expenses

Evinacumab-dgnb (Evkeeza-REGN1500), A Novel Lipid-Lowering Therapy for Homozygous Familial Hypercholesterolemia

Emerging lipid lowering agents targeting LDL cholesterol

Current Treatment Options in Homozygous Familial Hypercholesterolemia

How ANGPTL3 Inhibition Will Help Our Clinical Practice?

Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia

New approaches to address dyslipidemia

Suchergebnisse filtern